Metraipolis › archive › dc_edfa3fb4b39a

Growth inhibition associated with disruption of the actin cytoskeleton by Latrunculin A in rhabdomyosarcoma cells — Europe PMC PMID:32898143

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32898143
DOI
10.1371/journal.pone.0238572
License (as archived)
CC0-1.0
Archived
2026-11-07T14:07:19.742Z
SHA-256 of the archived text
fd0a8af4b350567fe7bfe18ffa01529abc2e8ef29df24548d06c9049777fffe5
Stable URL of this page
https://metraipolis.com/documento/dc_edfa3fb4b39a

How to cite

Growth inhibition associated with disruption of the actin cytoskeleton by Latrunculin A in rhabdomyosarcoma cells — Europe PMC PMID:32898143 — Europe PMC (en), https://europepmc.org/article/MED/32898143 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_edfa3fb4b39a (Metraipolis archive dc_edfa3fb4b39a, sha256 fd0a8af4b350567fe7bfe18ffa01529abc2e8ef29df24548d06c9049777fffe5)
BibTeX
@misc{dcedfa3fb4b39a,
  title = {Growth inhibition associated with disruption of the actin cytoskeleton by Latrunculin A in rhabdomyosarcoma cells — Europe PMC PMID:32898143},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32898143},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_edfa3fb4b39a; sha256 fd0a8af4b350567fe7bfe18ffa01529abc2e8ef29df24548d06c9049777fffe5},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32898143. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Functional genomic screening of KRAS-driven mouse sarcomas was previously employed to identify proliferation-relevant genes. Genes identified included Ubiquitin-conjugating enzyme E2 (Ube2c), Centromere Protein E (Cenpe), Hyaluronan Synthase 2 (Has2), and CAMP Responsive Element Binding Protein 3 Like 2 (Creb3l2). This study examines the expression and chemical inhibition of these candidate genes, identifying variable levels of protein expression and significant contributions to rhabdomyosarcoma (RMS) cell proliferation. Chemical treatment of human and murine RMS cell lines with bortezomib, UA62784, latrunculin A and sorafenib inhibited growth with approximate EC50 concentrations of 15-30nM for bortezomib, 25-80nM for UA62784 and 80-220nM for latrunculin A. The multi-kinase inhibitor sorafenib increased in vitro proliferation of 4 of 6 sarcoma cell lines tested. Latrunculin A was further associated with disruption of the actin cytoskeleton and reduced ERK1/2 phosphorylation. Together, this work advances opportunities for developing therapies to block progression of soft-tissue sarcomas and demonstrates that disruption of the actin cytoskeleton in sarcoma cells by latrunculin A is associated with a reduction in RMS cell growth. (167 words).

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-09-08).
Identificativi: PMID 32898143 · PMCID PMC7478754 · DOI 10.1371/journal.pone.0238572.
Pagina: https://europepmc.org/article/MED/32898143 — https://doi.org/10.1371/journal.pone.0238572. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-07T14:03:09.413Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.